Revenue Showdown: Teva Pharmaceutical Industries Limited vs Viridian Therapeutics, Inc.

Pharma Revenue Trends: Teva vs. Viridian

__timestampTeva Pharmaceutical Industries LimitedViridian Therapeutics, Inc.
Wednesday, January 1, 2014202720000004320000
Thursday, January 1, 2015196520000002538000
Friday, January 1, 2016219030000003337000
Sunday, January 1, 2017223850000004003000
Monday, January 1, 2018188540000008386000
Tuesday, January 1, 2019168870000004461000
Wednesday, January 1, 2020166580000001050000
Friday, January 1, 2021158780000002963000
Saturday, January 1, 2022149250000001772000
Sunday, January 1, 202315846000000314000
Monday, January 1, 202416544000000
Loading chart...

In pursuit of knowledge

Revenue Trends in Pharmaceuticals: A Comparative Analysis

In the ever-evolving pharmaceutical industry, revenue trends offer a glimpse into the financial health and market position of companies. Over the past decade, Teva Pharmaceutical Industries Limited and Viridian Therapeutics, Inc. have showcased contrasting revenue trajectories. From 2014 to 2023, Teva's revenue has seen a decline of approximately 22%, dropping from its peak in 2017. This trend reflects the challenges faced by established pharmaceutical giants in maintaining growth amidst patent expirations and increased competition.

Conversely, Viridian Therapeutics, a smaller player, has experienced fluctuating revenues, peaking in 2018. Despite a significant drop in 2023, Viridian's revenue journey highlights the volatility and potential for growth in emerging biotech firms. This comparison underscores the dynamic nature of the pharmaceutical sector, where both established and emerging companies navigate unique challenges and opportunities.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025